US2023257743A1PendingUtilityA1
Use of p38 inhibitors to reduce expression of dux4
Est. expiryOct 5, 2037(~11.2 yrs left)· nominal 20-yr term from priority
Inventors:Angela CacaceLuis Gustavo Alejandro Rojas SotoLorin A. Thompson, IiiOwen Brendan WallaceLucienne V. RoncoNing ShenAlan Scott RobertsonAaron Nakwon Chang
C12N 15/113A61P 21/00A61K 31/4418A61K 31/4439A61K 31/506A61K 31/519A61K 31/416A61K 31/437A61K 31/454A61K 31/496A61K 31/513A61K 31/53A61K 31/5377C12Q 1/6827C12Q 1/686C12Q 1/6883A61K 45/06A61K 45/00A61K 31/00G01N 33/5061C07K 14/4707C12N 9/12C12Y 207/11024G01N 33/68G01N 2500/10C12Q 2600/106C12Q 2600/156A61K 9/0019A61K 9/0053A61K 9/0073
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods of inhibiting p38 kinase to reduce gene and protein expression of DUX4 and downstream genes regulated by DUX4. The present invention further relates to methods for treating patients suffering from diseases associated with increased expression of DUX4 or expression of an aberrant form of DUX4, such as Facioscapulohumeral muscular dystrophy (FSHD).
Claims
exact text as granted — not AI-modified1 . A method of reducing the expression of a DUX4-fl mRNA, a DUX4 polypeptide, or a polypeptide encoded by a downstream target gene of DUX4, in a cell, comprising contacting the cell with an agent that results in a reduction of active p38 protein in the cell, thereby reducing expression the DUX4 polypeptide or the polypeptide encoded by the downstream target gene of DUX4.
2 . The method of claim 1 , wherein the agent inhibits the expression or activity, or reduces the amount, of the p38 protein, wherein the activity is optionally kinase activity.
3 . (canceled)
4 . The method of claim 1 , wherein the cell has an increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, as compared to the expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, in a control cell.
5 . The method of claim 4 , wherein the increased expression level of the DUX4-fl mRNA, the DUX4 polypeptide, or the polypeptide encoded by the downstream target gene, is due to reduced repression at a D4Z4 locus in the cell.
6 . The method of claim 1 , wherein the cell is associated with facioscapulohumeral muscular dystrophy (FSHD).
7 . The method of claim 6 , wherein the cell comprises a deletion of one or more macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35, optionally wherein the cell comprises ≤7 macrosatellite D4Z4 repeats in the subtelomeric region of chromosome 4q35.
8 . The method of claim 1 , wherein the cell comprises one or more mutations in a Structural Maintenance Of Chromosomes Flexible Hinge Domain Containing 1 (SMCHD1) gene.
9 . The method of claim 8 , wherein the cell comprises at least one non-deleted 4qA allele.
10 - 12 . (canceled)
13 . The method of claim 1 , wherein the agent inhibits the activity of the p38 protein.
14 . The method of claim 1 , wherein the agent binds the p38 protein.
15 . (canceled)
16 . The method of claim 1 , wherein the agent comprises a small molecule, optionally a small organic molecule or a small inorganic molecule.
17 . The method of claim 1 , wherein the downstream target gene is RFPL2, CCNA1, SLC34A2, TPRX1, KHDC1L, ZSCAN4, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15 or ZNF280A.
18 . The method of claim 1 , wherein the expression or the activity of the p38 protein is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%.
19 - 64 . (canceled)Join the waitlist — get patent alerts
Track US2023257743A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.